Fatima Afzal, Naseer Ahmad, Rana Naveed Iqbal, Fiza Azhar, Saqib Siddiq.
Intraocular Pressure changes following Intravitreal Injection of Bevacizumab.
Ophthalmol Update Jan ;14(4):131-4.

Objective: 1. To determine the frequency of patients with age related macular degeneration that show a rise in intraocular pressure at least 5mmHg above their baseline value at 30 minutes after intravitreal injection of bevacizumab. 2.To determine the frequency of these patients in whom intraocular pressure returns to baseline at 24 hours. Materials and Methods: This study was conducted in the department of ophthalmology Services Hospital Lahore, from July 2012 to December 2012.100 eyes of 100 patients fulfilling the inclusion criteria were selected for this study. The prepared 0.05ml of bevacizumab (1.25mg/0.05cc) in a tuberculin syringe was injected with a 27- gauge needle through the pars plana at 4mm or 3.5mm.away from the limbus. Then the intraocular pressure was measured using Goldman applanation tonometer 30 minutes post procedure, to determine the frequency of rise in intraocular pressure, and then after 24 hours to determine the frequency of those in whom intraocular pressure returned to baseline. Results: The mean age of the patients was 76.4�4.9 years. There were 68 (68.0%) male and 32 (32.0%) female patients. The mean baseline intraocular pressure (IOP) of the patients was 12.2�2.0 mmHg. The mean intraocular pressure at 30 minutes of the patients was 13.2�2.0 mmHg. There were 8 (8%) patients who had rise in IOP at 30 minutes. There were 8 (100%) patients, whose IOP at 24 hours returned to baseline. Conclusion: It was concluded from this study that intravitreal injection of bevacizumab is safe with respect to IOP changes, in case the IOP of patients rises after 30 minutes the majority of patients` IOP returned to baseline within 24 hours.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com